The technology described herein is directed to methods and compositions for the treatment of hypertension, e.g. pulmonary arterial hypertension, relating to inhibition of TGFβ1, TGFβ3, and/or GDF-15.La technologie de linvention concerne des procédés et des compositions pour le traitement de lhypertension, par exemple de lhypertension artérielle pulmonaire, impliquant linhibition de TGFβ1, TGFβ3, et/ou GDF-15.